This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Donald F. Phillips
JAMA contributor

JAMA. 1998;280:869-870.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

LEPTIN, the so-called antiobesity hormone, received a lot of attention at the American Diabetes Association's (ADA) 58th Scientific Sessions, held in Chicago, Ill, in June. The biggest news centered on results of phase 1 and 2 clinical trials, which showed that recombinant methionyl human leptin has an acceptable safety profile and causes dose-dependent weight loss.

"What makes this result exciting is that leptin is a natural human protein that has been suggested to have a role in regulating body weight," explained Andrew S. Greenberg, MD, director of the Program in Obesity and Metabolism at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University School of Medicine and director of research at the Obesity Consultation Center at New England Medical Center, both in Boston, Mass. "Obese participants taking the highest dose of the daily leptin injection lost an average of nearly 16 lb over . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reversing adipocyte differentiation: Implications for treatment of obesity
Zhou et al.
Proc. Natl. Acad. Sci. USA 1999;96:2391-2395.
ABSTRACT | FULL TEXT